

Human CD38 Monoclonal Antibody

Catalog No.: YR0007

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SEC-P

Purity

>95% Determined by SEC-HPLC

Background

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Daratumumab Biosimilar

Isotype

human IgG1 kappa

Immunogen

Human CD38

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.3

Contact

	400-999-6126
	cn.market@abclonal.com.cn
	www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility


Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD38 (Research Grade Daratumumab Biosimilar) Monoclonal Antibody to CD38. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Detection of CD38 in Human PBMCs cell line by Flow Cytometry. Human PBMCs cell line was stained with Biotinylated Human Anti-Human CD38 (Daratumumab Biosimilar) Monoclonal Antibody followed by APC conjugated NeutrAvidin Secondary Antibody, or unstained cells (open blue histogram).